Skip to content

Medical-device intelligence

QDC: Dna-Based Test For Minimal Residual Disease For Hematologic Malignancies

FDA product code QDC: Dna-Based Test For Minimal Residual Disease For Hematologic Malignancies. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
QDC
FDA device name
Dna-Based Test For Minimal Residual Disease For Hematologic Malignancies
Device class
2
Regulation number
866.6100
Medical specialty
Pathology
Review panel
PA

FDA definition

A DNA-based test for minimal residual disease is an in vitro diagnostic device that identifies and quantifies specific nucleic acid sequences isolated from human specimens to estimate the percentage of cells that harbor the specific sequence(s). The test is intended to be used as an aid to measure minimal residual disease to monitor the change in burden of disease for patients with a hematological malignancy during and after treatment. The results should be interpreted by a pathologist or equivalent professional in conjunction with other clinical and laboratory findings.
Explore pathology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

1 clearance records and 0 recall records in the covered releases, across 1 source company names and 1 product codes. Dated history runs from Aug 5, 2020 to Aug 5, 2020.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202600
September 202600
October 202600

Product codes represented

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

1 matching records
Device / recordCompany in FDA recordSourceSource date
Adaptive Biotechnologies clonoSEQ AssayK200009 · QDCAdaptive Biotechnologies Corporation510(k)Aug 5, 2020FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗